Back
Surgery Partners Quote, Financials, Valuation and Earnings
Sponsored
SGRY
Sponsored
Unlock the Secret to Earning Monthly Income!
Limited spots act swiftly
Sell
45
SGRY
Surgery Partners
Last Price:
24.55
Seasonality Move:
4.27%
7 Day Trial
ALL ACCESS PASS
$
7
NOW is the time to get in on this trillion-dollar megatrend
Get it here.Surgery Partners Price Quote
$24.55
Surgery Partners Key Stats
Sell
45
Surgery Partners (SGRY)
is a Sell
Day range:
$23.86 - $24.78
52-week range:
$22.05 - $45.79
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.13
P/B ratio:
1.56%
Volume:
604.3K
Avg. volume:
840.6K
1-year change:
-37.9%
Market cap:
$3.1B
Revenue:
$2.7B
EPS:
$-0.1
How Much Does Surgery Partners Make?
-
How Much Are Surgery Partners's Sales Annually?
SGRY Revenues are $2.7B -
How Much Profit Does Surgery Partners's Make A Year?
SGRY net income is -$11.9M
Is Surgery Partners Growing As A Company?
-
What Is Surgery Partners's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.04% -
What Is Surgery Partners's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Surgery Partners Stock Price Performance
-
Did Surgery Partners Stock Go Up Last Month?
Surgery Partners share price went down by -15.9% last month -
Did SGRY's Share Price Rise Over The Last Year?
SGRY share price fell by -37.9% over the past 1 year
What Is Surgery Partners 52-Week High & Low?
-
What Is Surgery Partners’s 52-Week High Share Price?
Surgery Partners has traded as high as $45.79 over the past 52 weeks -
What Is Surgery Partners’s 52-Week Low Share Price?
Surgery Partners has traded as low as $22.05 over the past 52 weeks
Surgery Partners Price To Free Cash Flow
-
Is Surgery Partners Stock Overvalued?
Surgery Partners is trading at a price to free cash flow ratio of 15.09 -
Is Surgery Partners Stock Undervalued?
Surgery Partners EV to Free Cash Flow ratio is 34.45 -
What Is Surgery Partners’s Price Earnings Growth Ratio?
SGRY PEG ratio is 0.00 -
Is Surgery Partners Trading At A Premium To Earnings?
Surgery Partners EV to EBIT ratio is 21.53
Is It Risky To Buy Surgery Partners?
-
How Much Debt Does Surgery Partners Have?
Total long term debt quarterly is $2.8B -
How Much Cash Does Surgery Partners Have?
Cash and short term investments quarterly total is $195.9M -
What Is Surgery Partners’s Book Value Per Share?
Book value per share is 15.70
Is Surgery Partners Cash Flow Positive?
-
What Is SGRY Cash Flow From Operations?
Cash flow from operations (TTM) is $293.8M -
What Is Surgery Partners’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$155.2M -
What Is Surgery Partners’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$225.6M
Surgery Partners Return On Invested Capital
-
Is Management Doing A Good Job?
SGRY return on invested capital is -0.2% -
What Is Surgery Partners Return On Assets?
ROA measures how assets are converting to revenues and is -0.18% -
What Is SGRY Return On Equity?
ROE is a measure of profitability and is -0.36%
Surgery Partners Earnings Date & Stock Price
-
What Is Surgery Partners's Stock Price Today?
A single share of SGRY can be purchased today for 24.55 -
What Is Surgery Partners’s Stock Symbol?
Surgery Partners trades on the nasdaq under the ticker symbol: SGRY -
When Is Surgery Partners’s Next Earnings Date?
The next quarterly earnings date for Surgery Partners is scheduled on May 7, 2024 -
When Is SGRY's next ex-dividend date?
Surgery Partners's next ex-dividend date is May 26, 2020 -
How To Buy Surgery Partners Stock?
You can buy Surgery Partners shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Surgery Partners Competitors
-
Who Are Surgery Partners's Competitors?
Below is a list of companies who compete with Surgery Partners or are related in some way:
Surgery Partners Dividend Yield
Data Unavailable
Surgery Partners Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 16.94% |
Revenue: | 4% | -0.82% |
Analyst Recommendations
Buy Recommendations: | 8 |
---|---|
Hold Recommendations: | 2 |
Sell Recommendations: | 0 |
Price Target: | 42.36 |
Upside from Last Price: | 72.56% |